Cambridge Investment Research Advisors’s Statera Biopharma, Inc. Common Stock STAB Stock Holding History

Cambridge Investment Research Advisors’s Portfolio STAB Stock Details STAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-59,825	Closed	-$5K	–	3311
2022 Q4	$5K	Sell	59,825 -9,000	-13%	-$1.14K	﹤0.01%	3087
2022 Q3	$9K	Hold	68,825	–	–	﹤0.01%	3027
2022 Q2	$20K	Sell	68,825 -1,421	-2%	-$367	﹤0.01%	3000
2022 Q1	$22K	Buy	70,246 +10,211	+17%	+$10.9K	﹤0.01%	3120
2021 Q4	$138K	Sell	60,035 -11,990	-17%	-$35.4K	﹤0.01%	2978
2021 Q3	$166K	Buy	72,025 +23,300	+48%	+$88.3K	﹤0.01%	2854
2021 Q2	$267K	Buy	48,725 +12,700	+35%	+$68.4K	﹤0.01%	2561
2021 Q1	$189K	Buy	+36,025	New	+$197K	﹤0.01%	2645
2015 Q1	–	Sell	-1,125	Closed	-$6K	–	1462
2014 Q4	$6K	Buy	1,125 +375	+50%	+$2.93K	﹤0.01%	1362
2014 Q3	$7K	Hold	750	–	–	﹤0.01%	1458
2014 Q2	$7K	Hold	750	–	–	﹤0.01%	1336
2014 Q1	$10K	Hold	750	–	–	﹤0.01%	1290
2013 Q4	$18K	Sell	750 -5	-0.7%	-$136	﹤0.01%	1226
2013 Q3	$24K	Hold	755	–	–	﹤0.01%	1185
2013 Q2	$24K	Buy	+755	New	+$26K	﹤0.01%	1093

Other funds holding STAB

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

TAM

Tucker Asset Management Littleton, Colorado $343M AUM 17.55% 1-Year Est. Return

Cambridge Investment Research Advisors's STAB Position: Q1 2023 in Review

Cambridge Investment Research Advisors sold out of Statera Biopharma, Inc. Common Stock (STAB) in Q1 2023, closing a stake of 59,825 shares — an estimated $5K sold.

Cambridge Investment Research Advisors first reported a position in STAB in Q2 2013 and held it in 15 quarters. The position peaked at $267K in Q2 2021. 4 funds tracked by Wall St. Rank hold STAB as of Q1 2023.

Cambridge Investment Research Advisors reported no remaining Statera Biopharma, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Cambridge Investment Research Advisors sold 59,825 Statera Biopharma, Inc. Common Stock shares in Q1 2023, an estimated $5K.
Cambridge Investment Research Advisors first reported a position in Statera Biopharma, Inc. Common Stock in Q2 2013 and held it in 15 quarters.
Cambridge Investment Research Advisors's Statera Biopharma, Inc. Common Stock position peaked at $267K in Q2 2021.
4 funds tracked by Wall St. Rank held Statera Biopharma, Inc. Common Stock as of Q1 2023.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2023, filed 11 May 2023.